vs
Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and Taylor Morrison Home Corp (TMHC). Click either name above to swap in a different company.
Taylor Morrison Home Corp is the larger business by last-quarter revenue ($1.4B vs $874.6M, roughly 1.6× BIOMARIN PHARMACEUTICAL INC). Taylor Morrison Home Corp runs the higher net margin — 7.1% vs -5.3%, a 12.4% gap on every dollar of revenue. On growth, BIOMARIN PHARMACEUTICAL INC posted the faster year-over-year revenue change (17.0% vs -26.8%). Over the past eight quarters, BIOMARIN PHARMACEUTICAL INC's revenue compounded faster (16.1% CAGR vs -16.5%).
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Taylor Morrison is one of the largest home building companies in the United States. Its corporate headquarters are in Scottsdale, Arizona. The company formed when Taylor Woodrow and Morrison Homes joined forces in July 2007. Taylor Morrison operates in Arizona, California, Colorado, Georgia, Florida, North Carolina, South Carolina, Nevada, Indiana, and Texas, building mid-to-upscale housing, as well as first-time and mid-market homes.
BMRN vs TMHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $874.6M | $1.4B |
| Net Profit | $-46.6M | $98.6M |
| Gross Margin | 68.5% | 21.0% |
| Operating Margin | -5.1% | — |
| Net Margin | -5.3% | 7.1% |
| Revenue YoY | 17.0% | -26.8% |
| Net Profit YoY | -137.3% | -53.8% |
| EPS (diluted) | $-0.22 | $1.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.4B | ||
| Q4 25 | $874.6M | $2.1B | ||
| Q3 25 | $776.1M | $2.1B | ||
| Q2 25 | $825.4M | $2.0B | ||
| Q1 25 | $745.1M | $1.9B | ||
| Q4 24 | $747.3M | $2.4B | ||
| Q3 24 | $745.7M | $2.1B | ||
| Q2 24 | $712.0M | $2.0B |
| Q1 26 | — | $98.6M | ||
| Q4 25 | $-46.6M | $174.0M | ||
| Q3 25 | $-30.7M | $201.4M | ||
| Q2 25 | $240.5M | $193.6M | ||
| Q1 25 | $185.7M | $213.5M | ||
| Q4 24 | $124.9M | $242.5M | ||
| Q3 24 | $106.1M | $251.1M | ||
| Q2 24 | $107.2M | $199.5M |
| Q1 26 | — | 21.0% | ||
| Q4 25 | 68.5% | 22.0% | ||
| Q3 25 | 82.0% | 22.7% | ||
| Q2 25 | 81.8% | 23.0% | ||
| Q1 25 | 79.7% | 24.4% | ||
| Q4 24 | 81.8% | 23.9% | ||
| Q3 24 | 74.7% | 25.0% | ||
| Q2 24 | 81.7% | 23.7% |
| Q1 26 | — | — | ||
| Q4 25 | -5.1% | — | ||
| Q3 25 | -6.0% | — | ||
| Q2 25 | 33.5% | — | ||
| Q1 25 | 30.0% | — | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 16.9% | — |
| Q1 26 | — | 7.1% | ||
| Q4 25 | -5.3% | 8.3% | ||
| Q3 25 | -4.0% | 9.6% | ||
| Q2 25 | 29.1% | 9.5% | ||
| Q1 25 | 24.9% | 11.3% | ||
| Q4 24 | 16.7% | 10.3% | ||
| Q3 24 | 14.2% | 11.8% | ||
| Q2 24 | 15.1% | 10.0% |
| Q1 26 | — | $1.12 | ||
| Q4 25 | $-0.22 | $1.77 | ||
| Q3 25 | $-0.16 | $2.01 | ||
| Q2 25 | $1.23 | $1.92 | ||
| Q1 25 | $0.95 | $2.07 | ||
| Q4 24 | $0.65 | $2.29 | ||
| Q3 24 | $0.55 | $2.37 | ||
| Q2 24 | $0.55 | $1.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $652.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.1B | $6.2B |
| Total Assets | $7.6B | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $652.9M | ||
| Q4 25 | $1.3B | $850.0M | ||
| Q3 25 | $1.3B | $370.6M | ||
| Q2 25 | $1.2B | $130.2M | ||
| Q1 25 | $1.0B | $377.8M | ||
| Q4 24 | $942.8M | $487.2M | ||
| Q3 24 | $675.4M | $256.4M | ||
| Q2 24 | $972.1M | $246.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $6.2B | ||
| Q4 25 | $6.1B | $6.3B | ||
| Q3 25 | $6.1B | $6.2B | ||
| Q2 25 | $6.0B | $6.1B | ||
| Q1 25 | $5.8B | $6.0B | ||
| Q4 24 | $5.7B | $5.9B | ||
| Q3 24 | $5.4B | $5.7B | ||
| Q2 24 | $5.3B | $5.5B |
| Q1 26 | — | $9.8B | ||
| Q4 25 | $7.6B | $9.8B | ||
| Q3 25 | $7.6B | $9.6B | ||
| Q2 25 | $7.5B | $9.5B | ||
| Q1 25 | $7.1B | $9.4B | ||
| Q4 24 | $7.0B | $9.3B | ||
| Q3 24 | $6.9B | $9.3B | ||
| Q2 24 | $7.1B | $9.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.36× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.6M | — |
| Free Cash FlowOCF − Capex | $58.9M | — |
| FCF MarginFCF / Revenue | 6.7% | — |
| Capex IntensityCapex / Revenue | 4.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $725.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $99.6M | $646.4M | ||
| Q3 25 | $368.7M | $219.6M | ||
| Q2 25 | $185.3M | $-126.0M | ||
| Q1 25 | $174.4M | $77.2M | ||
| Q4 24 | $185.6M | $438.2M | ||
| Q3 24 | $221.5M | $135.9M | ||
| Q2 24 | $118.8M | $-233.3M |
| Q1 26 | — | — | ||
| Q4 25 | $58.9M | $635.3M | ||
| Q3 25 | $340.2M | $206.6M | ||
| Q2 25 | $168.2M | $-133.6M | ||
| Q1 25 | $157.6M | $68.7M | ||
| Q4 24 | $166.1M | $428.2M | ||
| Q3 24 | $203.0M | $127.1M | ||
| Q2 24 | $97.4M | $-241.7M |
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 30.3% | ||
| Q3 25 | 43.8% | 9.9% | ||
| Q2 25 | 20.4% | -6.6% | ||
| Q1 25 | 21.2% | 3.6% | ||
| Q4 24 | 22.2% | 18.2% | ||
| Q3 24 | 27.2% | 6.0% | ||
| Q2 24 | 13.7% | -12.1% |
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | 0.5% | ||
| Q3 25 | 3.7% | 0.6% | ||
| Q2 25 | 2.1% | 0.4% | ||
| Q1 25 | 2.3% | 0.4% | ||
| Q4 24 | 2.6% | 0.4% | ||
| Q3 24 | 2.5% | 0.4% | ||
| Q2 24 | 3.0% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | 0.77× | -0.65× | ||
| Q1 25 | 0.94× | 0.36× | ||
| Q4 24 | 1.49× | 1.81× | ||
| Q3 24 | 2.09× | 0.54× | ||
| Q2 24 | 1.11× | -1.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
TMHC
| Home closings revenue, net | $1.3B | 95% |
| Financial services revenue, net | $49.3M | 4% |
| Land closings revenue | $14.5M | 1% |
| Amenity and other revenue | $11.9M | 1% |
